What is the 13F Pro Quality Score for DVA?

13F Pro ranks DAVITA INC. (DVA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DVA's current score at https://13fpro.ai/research/DVA (free sign-up required for the full ranking).

Which hedge funds own the most DVA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of DVA include BERKSHIRE HATHAWAY, BlackRock,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/DVA as soon as new 13F filings post.

Where does 13F Pro source DVA data?

All DAVITA INC. fundamentals and ownership data come directly from SEC EDGAR. DAVITA INC. files with the SEC under CIK 927066. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DVA in?

DAVITA INC. (DVA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DVA research updated on 13F Pro?

DVA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

DAVITA INC.(DVA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 927066 DVA stock profile & AI dashboard →

13F Pro Quality Score

57.5/100

Rank #1,035 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

53.0/100

Profitability

48.5/100

Balance Sheet

64.8/100

Earnings Quality

32.1/100

Free Cash Flow

59.4/100

Institutional Flow

15.0/100

Revenue Scale

89.3/100

Dilution Risk

56.6/100

DVA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for DAVITA INC. (DVA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DVA at 57.5/100 on a 32-signal composite quality model, placing it at rank #1,035 of 2,879 stocks — the top half of the AI-ranked universe. DVA scores in the top quartile across revenue scale (89.3). Areas of concern include institutional flow (15.0) and earnings quality (32.1), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), DAVITA INC. reports quarterly revenue of $3.4B, net income of $197.5M, an operating margin of 14.1%. Top institutional holders of DVA by reported 13-F value include BERKSHIRE HATHAWAY, BlackRock,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. DVA trades on the NYSE exchange and files with the SEC under CIK 927066. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DAVITA INC. directly from SEC EDGAR. DAVITA INC.'s 13F Pro composite quality score has ranged between 8 and 66 since 2021, currently 57.5 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about DAVITA INC.

Quirks, history, and lore behind DVA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare services company · large-cap · listed on the NYSE · headquartered in Colorado.
2
The Numbers
Revenue of roughly $12 billion a year, operating thousands of outpatient centers across the country and serving hundreds of thousands of patients.
3
The History
The company emerged from bankruptcy in the early 2000s, rebranded with a new name, and went on to become one of the largest independent operators in its niche treatment category.
4
The Secret
Its business depends almost entirely on government reimbursement — Medicare and Medicaid foot most of the bill, making regulatory decisions an existential sport.
5
The Lore
Warren Buffett's Berkshire Hathaway has held a significant stake, and the company famously calls its employees "teammates" and its centers "villages" — a culture unusually warm for a medical giant.
6
The Giveaway
Its name is a clever pun on "vita" (life), it runs more kidney dialysis clinics than almost anyone on Earth, and it keeps roughly 200,000 patients alive three times a week.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$3.4B

Net Income

Q1 2026

$197.5M

Free Cash Flow

Q1 2026

$218.8M

Operating Margin

Q1 2026

14.1%

ROIC

Q1 2026

4.9%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+6.5% YoY

$13.64BFY 2025

FY22 $11.61BFY23 $12.14BFY24 $12.82BFY25 $13.64B

Net Income

-20.2% YoY

$746.8MFY 2025

FY22 $560.4MFY23 $691.5MFY24 $936.3MFY25 $746.8M

Operating Income

-2.2% YoY

$2.04BFY 2025

FY22 $1.34BFY23 $1.60BFY24 $2.09BFY25 $2.04B

EPS (Diluted)

-8.3% YoY

$9.84FY 2025

FY22 $5.85FY23 $7.42FY24 $10.73FY25 $9.84

Total Assets

+1.1% YoY

$17.48BFY 2025

FY22 $16.93BFY23 $16.89BFY24 $17.29BFY25 $17.48B

Total Debt

+8.7% YoY

$10.27BFY 2025

FY22 $8.92BFY23 $8.39BFY24 $9.45BFY25 $10.27B

Op. Cash Flow

-6.7% YoY

$1.89BFY 2025

FY22 $1.56BFY23 $2.06BFY24 $2.02BFY25 $1.89B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$13.64B +6.5%	$12.82B +5.6%	$12.14B +4.6%	$11.61B -0.1%	$11.62B +0.6%	$11.55B
Net Income	$746.8M -20.2%	$936.3M +35.4%	$691.5M +23.4%	$560.4M -42.7%	$978.5M +26.5%	$773.6M
Operating Income	$2.04B -2.2%	$2.09B +30.4%	$1.60B +19.7%	$1.34B -25.5%	$1.80B +6.1%	$1.69B
EPS (Diluted)	$9.84 -8.3%	$10.73 +44.6%	$7.42 +26.8%	$5.85 -34.3%	$8.90 +41.0%	$6.31
Total Assets	$17.48B +1.1%	$17.29B +2.3%	$16.89B -0.2%	$16.93B -1.1%	$17.12B +0.8%	$16.99B
Total Debt	$10.27B +8.7%	$9.45B +12.6%	$8.39B -6.0%	$8.92B +0.2%	$8.91B +10.2%	$8.09B
Operating Cash Flow	$1.89B -6.7%	$2.02B -1.8%	$2.06B +31.6%	$1.56B -19.0%	$1.93B -2.4%	$1.98B

AI Insight: DVA Financial Trends

DaVita's revenue grew 7% year-over-year to $3,416M in Q1 2026, but equity turned deeply negative at -$755M as debt climbed to $10,626M.

• Revenue expanded steadily from $3,187M in Q2 2024 to $3,416M in Q1 2026, a ~7% rise over seven quarters.

• Equity deteriorated sharply from $633M in Q2 2024 to -$755M in Q1 2026, signaling persistent balance-sheet erosion.

• Total debt rose from $8,990M in Q2 2024 to $10,626M in Q1 2026, a $1,636M increase in under two years.

• Operating cash flow remains volatile: $842M in Q3 2025 but collapsed to $180M in Q1 2025 and $321M in Q1 2026.

⚠ Negative and deepening equity (-$755M in Q1 2026) combined with rising debt raises structural leverage risk.

⚠ Net income fell to $150M in Q3 2025, the lowest in the period — monitor whether Q4 2025 rebound is sustained.

⚠ Operating income dipped to $482M in Q1 2026 from $561M in Q4 2025 — first sequential decline in two quarters.

AI Insight: DVA Ratio Trends

DaVita's margins are tracking below peak Q4 2024 levels, with Q1 2026 operating margin of 14.1% and ROIC of 19.5% both near recent lows.

• Operating margin peaked at 17.2% in Q4 2024 but has since declined to 14.1% in Q1 2026, a 3.1pp contraction.

• ROIC followed a similar arc: rising to 23.6% in Q4 2024, then falling to 19.5% in Q1 2026, a 4.1pp drop.

• Net profit margin compressed from 7.9% in Q4 2024 to 5.8% in Q1 2026, with Q3 2025 touching a low of 4.4%.

• Q1 seasonality appears persistent: Q1 2025 and Q1 2026 both show the weakest operating margins in their respective years.

⚠ ROIC dropped to 19.5% in Q1 2026 — the lowest reading since Q1 2025's 18.5% — reversing Q4 2024's 23.6% peak.

⚠ D/E data is largely absent after Q3 2024's elevated 24.71x reading; leverage trajectory remains unclear and warrants monitoring.

⚠ Whether Q2 2025's partial margin recovery to 15.9% operating margin repeats in Q2 2026 will signal if seasonal troughs are stabilizing.

Get alerted when DVA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for DAVITA INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DVA

BERKSHIRE HATHAWAY INC
$4.6B30,100,585 sh
BlackRock, Inc.
$425.2M2,766,751 sh
VANGUARD CAPITAL MANAGEMENT LLC
$335.1M2,180,225 sh
MORGAN STANLEY
$256.1M1,666,038 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$227.4M1,479,600 sh
Invesco Ltd.
$225.6M1,467,881 sh
STATE STREET CORP
$207.7M1,351,737 sh
DIMENSIONAL FUND ADVISORS LP
$176.0M1,145,436 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$170.6M1,110,151 sh
GEODE CAPITAL MANAGEMENT, LLC
$144.2M939,781 sh

Fund	Value	Shares
BERKSHIRE HATHAWAY INC	$4.6B	30,100,585
BlackRock, Inc.	$425.2M	2,766,751
VANGUARD CAPITAL MANAGEMENT LLC	$335.1M	2,180,225
MORGAN STANLEY	$256.1M	1,666,038
VANGUARD PORTFOLIO MANAGEMENT LLC	$227.4M	1,479,600
Invesco Ltd.	$225.6M	1,467,881
STATE STREET CORP	$207.7M	1,351,737
DIMENSIONAL FUND ADVISORS LP	$176.0M	1,145,436
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$170.6M	1,110,151
GEODE CAPITAL MANAGEMENT, LLC	$144.2M	939,781

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DVA on your watchlist

Track score changes the day DAVITA INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DVA a good stock to buy?

13F Pro's AI-powered analysis of DAVITA INC. (DVA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DVA are available on the DVA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own DVA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DVA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DAVITA INC.'s investment landscape.